INTRODUCTION:
The phospholipase A2 Group 6 (PLA2G6, also known as PLA2, PARK14, and iPLA2) gene encodes a group via calcium-independent phospholipase A2. Genetic polymorphism of PLA2G6 has been indicated to be involved in conferring susceptibility for Parkinson’s disease (PD), whereas conclusive results have not been obtained.
OBJECTIVE:
To conduct a systematic review to determine if PLA2G6 genetic variation confers greater susceptibility to PD.
STUDY DESIGN:
A systematic review using meta-analysis was conducted.
METHOD:
Eight eligible studies fulfilling the inclusion criteria including 2,779 PD patients and 3,291 controls were considered for the review.
RESULTS:
- The study comprehensively summarized the genotype and allele frequencies of a total of 27 single nucleotide polymorphism (SNPs) in PLA2G6 gene.
- Among all the reported 27 genetic variants, 15 single nucleotide polymorphisms (SNPs) were present only in patients, and only five available SNPs (rs2267369, rs140758033, c.1959T>A (Gly653Gly), rs76718524, rs199935023) were pooled in the meta-analysis.
- However, there was no evidence of a significant association between the five SNPs and PD risk in dominant, codominant and allele models, suggesting a lack of association between PLA2G6 genetic variation and PD susceptibility.
- Sensitive analyses on rs2267369 and rs140758033, the only two SNPs which were included in three or more studies available for meta-analysis, was conducted by sequentially excluding each case-control study, and the results of all the three genetic models were consistent, suggesting the credibility and stability of this meta-analysis of the overall population and subgroup.
CONCLUSION:
The present study assessed the association of PLA2G6 genetic polymorphism with the risk PD, and the result strongly demonstrates that PLA2G6 polymorphism is not associated with PD susceptibility.